Printer Friendly

PHARMOS' TREATMENT SHOWS EFFICACY IN GIANT PAPILLARY CONJUNCTIVITIS; PHARMOS REPORTS DATA FROM CLINICAL STUDIES

 JERUSALEM, June 25 /PRNewswire/ -- At the International Conference on Cornea, Eye Banking and External Diseases here, Pharmos (NASDAQ: PARS), presented the results of a clinical trial testing the use of loteprednol etabonate (LE), currently in Phase III trials in the U.S., in treating contact lens associated giant papillary conjunctivitis (GPC).
 The study consisted of 110 patients with bilateral GPC enrolled in a multi-center, randomized, double-masked, placebo controlled, parallel group compensation of the LE ophthalmic suspension and a placebo. Patients enrolled in the study receiving the LE treatment demonstrated markedly significant reduction in the primary ocular signs of GPC. The treatment did not increase intraocular pressure. Patient compliance, which is a major concern with topical corticosteroids, was shown to be statistically higher with Pharmos' new treatment.
 GPC is a type of inflammation commonly experienced by contact lens wearers, particularly those with soft lenses. The condition results from protein deposits that form on the lens as a result of inadequate cleansing. These protein deposits cause papillae to form under the upper eyelid resulting in inflammation.
 Corticosteroids, such as LE, are commonly used in the treatment of ocular inflammation, but produce numerous side effects that limit their usefulness. One such side effect evoked by corticosteroid use is elevated intraocular pressure (IOP) which may lead to glaucoma and eventually cataracts. Pharmos' new drug appears to limit these side effects.
 "LE is designed according to a proprietary new drug concept so that it reduces inflammation in the eye and rapidly deactivates in the body thereafter, resulting in a much safer drug," says Dr. Haim Aviv, CEO of Pharmos.
 Pharmos researchers are presenting a second study at the Jerusalem conference using the company's SubMicron Emulsion (SME) drug delivery technology in combination with several well known topical ophthalmic drugs. The study shows reduced ocular irritation while maintaining or improving penetration of selected ophthalmic drugs. This is significant because researchers have implicated both the delivery of drugs and the active ingredients in the ocular inflammation that follows the use of many topical ophthalmic drugs.
 Pharmos Corporation is engaged in the development of novel pharmaceuticals based on innovative drug delivery technologies targeting diseases of the eye, principally glaucoma and ocular inflammation, and the brain, principally stroke and head trauma.
 -0- 6/25/93
 /CONTACT: Stephen R. Streber, president and COO of Pharmos, 212- 838-0087; Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212- 979-9180, for Pharmos; or Donald C. Weinberger, of Strategic Growth International, 212-826-9622, for Pharmos/
 (PARS)


CO: Pharmos Corporation ST: New York IN: MTC SU:

MP-LG -- NY017 -- 5683 06/25/93 11:18 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 25, 1993
Words:429
Previous Article:PIPER JAFFRAY INCOME INDEX (In Percents)
Next Article:PURE TECH NOT DISCUSSING SALE OF COMPANY
Topics:


Related Articles
PHARMOS CORPORATION CONTINUING PROGRESS IN OPHTHALMIC RESEARCH
PHARMOS CORPORATION PRESENTS FIRST STUDIES ON NOVEL ANTIGLAUCOMA NEUROPROTECTIVE AGENT
PHARMOS CORPORATION ADDRESSES KEY COMPLIANCE ISSUES WITH SME TECHNOLOGY
PHARMOS RESEARCHERS PRESENT DATA ON THE THERAPEUTIC VALUE OF HU-211, A NEUROPROTECTANT IN HEAD TRAUMA AND STROKE
PHARMOS ANNOUNCES MARKETING/PRODUCTION ARRANGEMENT WITH BAUSCH & LOMB FOR NOVEL OPHTHALMIC TREATMENT
PHARMOS ANNOUNCES THE SUCCESSFUL COMPLETION OF PHASE III CLINICAL TRIALS FOR LOTEMAX
PHARMOS PRESENTS LOTEMAX CLINICAL RESULTS AT ARVO CONVENTION
PHARMOS ANNOUNCES COMPLETION OF PHASE III STUDIES FOR NEW PRODUCT TO TREAT ALLERGIES OF THE EYE
Pharmos Commences Patient Dosing in Phase 2a Cannabinor Nociceptive Pain Study.
Pharmos Corporation to Present at the C.E. Unterberg Towbin Life Sciences Conference.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters